Inventiva gets a surprise hit in Nash
Inventiva’s mid-stage win has revived hopes for PPAR agonists in the liver disease, although safety questions remain.
Genfit’s predictable liver disease failure sets up a cirrhosis pivot
Five years after failing phase II in Nash, elafibranor fails phase III in Nash; a focus on liver cirrhosis beckons.
Upcoming events – Fibroid data for Obseva, as Inventiva turns to Nash
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
As Nash shifts again, the focus remains on Genfit’s big readout
Genfit investors, who early next year will see the Resolve-It study yield data, digest further developments in the Nash space.
Cymabay is out, but for Genfit the band plays on
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
Genfit’s liver disease Hail Mary approaches
Genfit's quiet delay means it will be five years since a Nash failure before investors find out whether pressing on into phase III was worth it.
As Genfit deals and Conatus folds, Nash plays on
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
Cymabay can’t buck the Nash disappointment trend
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
